What is the primary PK objective of extended-release formulations?

What is the primary PK objective of extended-release formulations?

• A. To slow and prolong drug absorption, flatten Cmax, and maintain more stable plasma concentrations with less frequent dosing
• B. To increase Cmax and shorten half-life
• C. To reduce bioavailability
• D. To cause erratic absorption

Answer: (A)

Extended-release formulations are designed to release the drug more slowly after administration, spreading absorption over a longer period. The goal is to flatten the concentration–time profile: a slower rise to a lower peak (lower Cmax) and a longer duration above the therapeutic threshold, which keeps plasma levels within the therapeutic window. This approach allows less frequent dosing while preserving overall exposure and efficacy, and it reduces peak-related side effects by avoiding high Cmax. The other outcomes described—raising the peak, shortening the half-life, reducing bioavailability, or causing erratic absorption—would not achieve the steady, prolonged effect that extended-release systems aim for.

Extended-release formulations are designed to release the drug more slowly after administration, spreading absorption over a longer period. The goal is to flatten the concentration–time profile: a slower rise to a lower peak (lower Cmax) and a longer duration above the therapeutic threshold, which keeps plasma levels within the therapeutic window. This approach allows less frequent dosing while preserving overall exposure and efficacy, and it reduces peak-related side effects by avoiding high Cmax. The other outcomes described—raising the peak, shortening the half-life, reducing bioavailability, or causing erratic absorption—would not achieve the steady, prolonged effect that extended-release systems aim for.